You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum-Sensitive Recurrent Ovarian Cancer

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Anchorage, Alaska
  • +55 more
Jul 25, 2022

Cytoreductive Surgery Trial in Hangzhou (cytoreductive surgery)

Not yet recruiting
  • Cytoreductive Surgery
  • cytoreductive surgery
  • Hangzhou, China
  • +1 more
Nov 30, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Oklahoma City (Paclitaxel, Cisplatin IP)

Terminated
Has Results
  • Ovarian Cancer
  • +3 more
  • Paclitaxel, Cisplatin IP
  • Oklahoma City, Oklahoma
    University of Oklahoma Health Sciences Center
Apr 28, 2021

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • (no location specified)
Oct 27, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Germany, Italy (Niraparib)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Berlin, Germany
  • +11 more
Sep 15, 2021

Ovarian Cancer Trial in Houston (Nivolumab, Etigilimab)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed

Completed
  • Ovarian Neoplasm
  • +4 more
    • (no location specified)
    Aug 22, 2022

    Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

    Active, not recruiting
    • Relapsed Ovarian Cancer
    • +2 more
    • Olaparib 300mg tablets
    • Beijing, China
    • +24 more
    Dec 5, 2022

    Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

    Recruiting
    • Platinum-Refractory Fallopian Tube Carcinoma
    • +11 more
    • Copanlisib Hydrochloride
    • +4 more
    • Aurora, Colorado
    • +2 more
    Dec 8, 2022

    Platinum-resistant Recurrent Ovarian Cancer Trial in Wuhan (Docetaxel for injection (Albumin-bound), Bevacizumab)

    Recruiting
    • Platinum-resistant Recurrent Ovarian Cancer
    • Wuhan, Hubei, China
      Tongji Hospital,Tongji Medical College of HUST
    Oct 12, 2022

    Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

    Recruiting
    • Ovarian Cancer
    • NKG2D CAR-NK
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Mar 26, 2023

    Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

    Terminated
    Has Results
    • Platinum Sensitive Ovarian Cancer
    • Ovarian Cancer
    • FRα peptide plus Adjuvant (GM-CSF)
    • Adjuvant (GM-CSF) Alone
    • Birmingham, Alabama
    • +17 more
    Nov 21, 2022

    A Real-World Patient-Reported Outcomes Study in Long-Term Use of

    Recruiting
    • Ovarian Cancer
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 13, 2023

      Platinum-resistant Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • pegylated liposomal doxorubicin
      • (no location specified)
      Aug 2, 2023

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Completed
      Has Results
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +8 more
      • Bevacizumab
      • Irinotecan Sucrosofate
      • Chicago, Illinois
        Northwestern University
      Dec 21, 2022

      Ovarian Cancer Trial in Maywood (Minoxidil)

      Recruiting
      • Ovarian Cancer
      • Maywood, Illinois
        Loyola University Medical Center
      Jun 23, 2022

      Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Shanghai (Hepato-celiac lymphadenectomy)

      Not yet recruiting
      • Epithelial Ovarian Cancer
      • +2 more
      • Hepato-celiac lymphadenectomy
      • Shanghai, China
        Zhongshan Hospital, Fudan University
      Feb 9, 2022

      Epithelial Ovarian Cancer Trial in Goyang-si (HIPEC)

      Recruiting
      • Epithelial Ovarian Cancer
      • HIPEC
      • Goyang-si, Gyeonggi-do, Korea, Republic of
        Myong Cheol Lim
      Apr 23, 2022

      Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)

      Active, not recruiting
      • Ovarian Cancer
      • Platinum-resistant Ovarian Cancer
      • Minsk, Belarus
        Minsk City Clinical Oncology Center
      Jul 27, 2023

      Ovarian Cancer, Breast Cancer Trial in India (Olaparib)

      Completed
      • Ovarian Cancer
      • Breast Cancer
      • Ahmedabad, India
      • +15 more
      Oct 28, 2022

      Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer Trial in Worldwide (Tumor Debulking Surgery (surgery in

      Completed
      • Fallopian Tube Cancer
      • +2 more
      • Tumor Debulking Surgery (surgery in recurrent ovarian disease)
      • Graz, Austria
      • +85 more
      Jan 21, 2022

      Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

      Not yet recruiting
      • Relapsed Ovarian Cancer
      • (no location specified)
      Jul 27, 2022

      Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)

      Not yet recruiting
      • Ovarian Cancer, Epithelial
      • Nanjing, Jiangsu, China
        Zhongda Hospital
      Jun 13, 2022

      Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

      Recruiting
      • Platinum-Resistant Fallopian Tube Carcinoma
      • +6 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      May 17, 2022